Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib Prophylaxis After HCT for Ph+ Leukemias
NCT00702403Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2008
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), sponsored by Fred Hutchinson Cancer Center. Started Aug 2008; status: completed.
02
Drugs
nilotinib
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00702403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702403.